Diogo Camacho’s Post

View profile for Diogo Camacho

Biotech Executive | Comp Bio | AI/ML | Computing Biology

There’s a lot to unpack here, but the open ended questions/comments that are left in this piece alone make you think: - how much more data generation will this trigger? - if the results are “meh” with 60 patients, why would they be stellar in a larger cohort? How would you pick that cohort, since it’s a rare disease? And many many other questions… #ai #drugdiscovery #biologyishard

With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug

With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug

endpts.com

To view or add a comment, sign in

Explore topics